eligibility_summary
Adults 18–70 with relapsed/refractory CD19+ B‑cell NHL (DLBCL, PMBCL, TFL, HGBCL, FL, MCL, MZL), measurable disease, ECOG≤2, adequate organ function, prior anti‑CD20+anthracycline (MCL also BTKi, or bendamustine). Exclude: survival<3m, allo‑SCT, auto‑SCT<3m, cell therapy<3m, chemo<2w, mAbs/ADC/bispecific<3w, RT<6w, CNS involvement, active infections incl HIV/HBV/HCV/EBV/CMV, cardiac dz, autoimmunity/immunodeficiency, VTE/PE<6m, vaccine<6w, urgent therapy need, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06323525 (ATHENA‑2). Intervention: Allogeneic, gene‑edited CD19‑targeting CAR‑T cells that retain endogenous T‑cell receptor (TCR) and knock out SPPL3 (Power3). Type: Biological cell therapy (allogeneic CAR‑T). Mechanisms: CAR mediates CD19‑specific cytotoxicity against malignant B cells, preserving TCR leverages tonic TCR/CAR signaling to enhance persistence, SPPL3 knockout reduces HLA‑mismatched fratricide and mitigates graft‑versus‑host and host T‑cell–mediated rejection, supporting expansion of donor CAR‑T cells. Targets/cells/pathways: CD19 on B cells, donor T‑cell TCR signaling (retained), SPPL3 pathway in T cells affecting alloreactivity/immune evasion, indirectly suppresses host B‑cell recovery. Conditioning drugs: Fludarabine (purine antimetabolite DNA synthesis inhibitor) and cyclophosphamide (alkylating agent) for lymphodepletion. Population: adults with r/r B‑cell NHL.